Catalog No.: PC-22474Not For Human Use, Lab Use Only.
WJ-39 (Darirestat potassium salt) is a small molecule aldose reductase (AR) inhibitor, does not affect AR protein expression, reduces oxidative stress by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.
WJ-39 (Darirestat potassium salt) is a small molecule aldose reductase (AR) inhibitor, does not affect AR protein expression, reduces oxidative stress by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. WJ-39 treatment ameliorated streptozotocin- (STZ-) induced renal inflammation in diabetic nephropathy (DN) rats. WJ-39 suppressed the activation of the nuclear factor-kappa B (NF-κB) pathway and the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome to reduce the secretion of inflammatory factors. WJ-39 alleviated inflammation via the Nrf2 pathway in rat mesangial cells cultured under high glucose (HG) conditions. WJ-39 treatment prevented renal fibrosis by suppressing the TGF-β1/Smad pathway in diabetic nephropathy (DN). WJ-39 reduced oxidative stress in the kidneys of DN rats by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. WJ-39 ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling.
Physicochemical Properties
M.Wt
430.32
Formula
C19H14Cl2KNO4
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
1(4H)-Quinolineacetic acid, 3-[(2,3-dichlorophenyl)methyl]-6-methoxy-4-oxo-, potassium salt (1:1)
References
1. Yang L, et al. Eur J Pharmacol. 2024 Mar 15;967:176376.
2. Zhou X, et al. Oxid Med Cell Longev. 2020 May 30;2020:7950457.
